|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | C12P 21/00 | (2006.01) |
| C12P 21/00 | (2013.01) | ||
| C12P 21/08 | (2006.01) | ||
| C07K 16/00 | (2006.01) |
| (11) | Number of the document | 3559248 |
| (13) | Kind of document | T |
| (96) | European patent application number | 17829955.8 |
| Date of filing the European patent application | 2017-12-19 | |
| (97) | Date of publication of the European application | 2019-10-30 |
| (45) | Date of publication and mention of the grant of the patent | 2021-11-17 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/EP2017/083429 |
| Date | 2017-12-19 |
| (87) | Number | WO 2018/114877 |
| Date | 2018-06-28 |
| (30) | Number | Date | Country code |
| 16205587 | 2016-12-21 | EP | |
| 17157002 | 2017-02-20 | EP |
| (72) |
FALKENSTEIN, Roberto , DE
WALCH, Heiko , DE
MALIK, Sebastian , DE
THOMANN, Marco , DE
FREIHERR VON ROMAN, Matthias , DE
GRUNERT, Ingrid , DE
DORN, Roland , DE
HINGAR, Michael , DE
|
| (73) |
F. Hoffmann-La Roche AG ,
Grenzacherstrasse 124, 4070 Basel,
CH
|
| (54) | IN VITRO GLYCOENGINEERING OF ANTIBODIES |
| IN VITRO GLYCOENGINEERING OF ANTIBODIES |